Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection
There are 257 million persons worldwide with chronic hepatitis B virus (HBV) infection, a leading causes of liver cancer. Almost all adults with acute HBV infection have a rapid immune response to the virus, resulting in life-long immunity, but there is no cure for individuals with chronic HBV infection, which they acquire during early life. The mechanisms that drive the progression of HBV through distinct clinical phases to end-stage liver disease are poorly understood. Likewise, it is not clear whether and how immune responses can be modulated to allow control and/or clearance of intrahepatic HBV DNA.
Source: Gastroenterology - Category: Gastroenterology Authors: Barbara Rehermann, Robert Thimme Tags: Viral Hepatitis and Hepatocellular Carcinoma Source Type: research
More News: Antiviral Therapy | Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Urology & Nephrology